REFERENCE:

- [1] Takeuchi T, et al. Ann Rheum Dis 2016; 75: 1057–64

Acknowledgement: This study was sponsored by Astellas Pharma, Inc. Medical writing support was provided by Rhian Harper Owen of Cello Health MedErgy and funded by Astellas Pharma, Inc.

Disclosure of Interests: Tsutomu Takeuchi Grant/research support from: Astellas Pharma Inc, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Co., Ltd., AbbVie GK, Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Eisai Co., Ltd., AYUMI Pharmaceutical Corporation, Nipponkayaku Co. Ltd., Novartis Pharma K.K., Grant/research support from: AbbVie, Asahi Kasei, Astellas, AstraZeneca, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lilly Japan, Janssen, Mitsubishi Tanabe, Nippon Kayaku, Novartis, Pfizer Japan Inc, Taiho, Taisho Toyama, Takeda, Teijin, Grant/research support from: Astellas Pharma Inc., Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., AbbVie GK, Asahi Kasei Pharma Corp., Taisho Toyama Pharmaceutical Co. Ltd., GlaxoSmithKline K.K., UCB Japan Co. Ltd., Consultant for: AbbVie, Asahi Kasei, Astellas, AstraZeneca, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lilly Japan, Janssen, Mitsubishi Tanabe, Nippon Kayaku, Novartis, Pfizer Japan Inc, Taiho, Taisho Toyama, Takeda, Teijin, Consultant for: Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Co., Asahi Kasei Medical K.K., AbbVie GK, Daiichi Sankyo Co., Ltd., Bristol Myers Squibb, and Nipponkayaku Co. Ltd., Speakers bureau: Astellas Pharma Inc., Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., AbbVie GK, Asahi Kasei Pharma Corp., Taisho Toyama Pharmaceutical Co., Ltd., Symbio Pharmaceuticals Ltd., Janssen Pharmaceutical K.K., Celltrion Inc., Nipponkayaku Co. Ltd., and UCB Japan, Speakers bureau: AbbVie, Asahi Kasei, Astellas, AstraZeneca, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lilly Japan, Janssen, Mitsubishi Tanabe, Nippon Kayaku, Novartis, Pfizer Japan Inc, Taiho, Taisho Toyama, Takeda, Teijin, Speakers bureau: AbbVie GK., Bristol-Myers K.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Astellas Pharma Inc, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sanofi K.K., Teijin Pharma Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K., Yoshiya Tanaka Grant/research support from: Abbvie, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, MSD, Ono, Taisho-Toyama, Takeda, Speakers bureau: Abbvie, Asahi-kasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eli Lilly, Eisai, Glaxo-Smithkline, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer Japan Inc, Sanofi, Takeda, UCB, YL Biologics, Sakae Tanaka Grant/research support from: KYOCERA Corporation and Asahi Kasei Corporation, Consultant for: Amgen Astellas BioPharma K.K., KYOCERA Corporation, Pfizer and Daiichi Sankyo Co., Ltd., Speakers bureau: Asahi Kasei Corporation, Astellas Pharma Inc, Ayumi Pharmaceutical Corporation, Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd, Taisho Toyama Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Eli Lilly, Hisamitsu Pharmaceutical Co., Inc., Pfizer, Bristol-Myers., Atsushi Kawakami Grant/research support from: Astellas Pharma, Consultant for: Astellas Pharma, Speakers bureau: Astellas Pharma, Manabu Iwasaki: None declared, Mitsuhiro Rokuda Employee of: Astellas Pharma, Inc., Hiroyuki Izutsu Employee of: Astellas Pharma, Inc., Satoshi Ushijima Employee of: Astellas Pharma, Inc., Yuichiro Kaneko Employee of: Astellas Pharma, Inc., Teruaki Shiomi Employee of: Astellas Pharma, Inc., Emi Yamada Employee of: Astellas Pharma, Inc.

DOI: 10.1136/annrheumdis-2019-eular.1580

OP0027

EFFECT OF SHORT-TERM METHOTREXATE DISCONTINUATION ON THE DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: POSTHOC-ANALYSIS OF TWO RANDOMIZED CLINICAL TRIALS

Min Jung Kim, Yeong Wook Song, Eun Bong Lee, Jin Kyun Park. Seoul National University Hospital, Seoul, Division of Rheumatology, Department of Internal Medicine, Seoul, Korea, Rep. of (South Korea)

Background: Patients with rheumatoid arthritis (RA) require a continuous, potentially life-long immune suppression with disease modifying antirheumatic drugs (DMARDs) including methotrexate (MTX). However, in special circumstances such as life-threatening infections, vaccinations or major surgeries, use of MTX should be minimized to restore the treatment-associated immune suppression. While a long-term or permanent discontinuation of MTX is associated with a

disease flare or relapse, the effect of short-term discontinuation on disease activity has not been fully elucidated.

Objectives: To investigate the effect of short-term discontinuation of MTX on the disease activity in patients with RA on stable dose of MTX.

Methods: This is a posthoc analysis of 2 randomized controlled studies investigating effect of MTX discontinuation for 2 weeks or 4 weeks on vaccine response to seasonal influenza vaccination in patients with RA. In the 4-week discontinuation study, 54 patients continued MTX and 44 patients discontinued it for 4 weeks before vaccination with trivalent seasonal influenza vaccine. In the 2-week discontinuation study, 159 patients continued MTX and 161 patients held it for 2 weeks after a seasonal quadrivalent influenza vaccine. Disease activity (DAS28 change, DAS28 flare rate and flare-free survival) was compared between the patients who continued MTX and those held it. A RA flare was defined as an increase in DAS28 of >1.2 or >0.6 if the baseline DAS28 was ≥ 3.2 .

Results: In the 4-week MTX-hold group, the mean DAS28 increased at the 4 weeks after MTX discontinuation by 0.38 ± 0.94 and then improved back to baseline after reintroduction of MTX, whereas the mean DAS28 in the MTX-continue group remained stable over time (Figure 1A). The overall flare-free survival during 20 weeks did not differ between the groups (log rank $p=0.142$) (Figure 1B). However, numerically more patients in the MTX-hold group experienced a flare than those in the MTX-continue group during the 4-weeks MTX discontinuation (20.5% vs. 7.4%, $p=0.058$). After resuming MTX, the flare rate did not differ between the groups up to 20 weeks of observations (Figure 1C). A temporary MTX discontinuation for 2 weeks was not associated with any clinically meaningful change in disease activity.

Figure 1. Changes in disease activity of rheumatoid arthritis after MTX discontinuation over time. (A) DAS28-CRP and (B) RA flare free survival in the MTX continue and the MTX hold group were depicted. (C) RA flare rates over time were shown. MTX, methotrexate.

Conclusion: A short-term MTX discontinuation for 2 weeks is safe without any change in disease activity. A 4-week MTX discontinuation is associated with transient increase in disease activity without affecting long-term outcomes.

REFERENCES:

- Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017 May 03.
- Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018 Jun; 77(6):898-904.
- Haschka J, Englbrecht M, Hueber AJ, Manger B, Kleyer A, Reiser M, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016 Jan; 75(1):45-51.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.2524

OP0028

POST-APPROVAL COMPARATIVE SAFETY STUDY OF TOFACITINIB AND BIOLOGIC DMARDs: FIVE-YEAR RESULTS FROM A US-BASED RHEUMATOID ARTHRITIS REGISTRY

Joel Kremer¹, Clifton Bingham², Laura Cappelli², Carol Etzel³, Jeffrey Greenberg³, Jamie Geier⁴, Ann Madsen⁴, Connie Chen⁴, Alina Onofrei³, Christine Barr³, Dimitrios A. Pappas⁵, Heather J. Litman³, Kimberly J. Dandreo³, Andrea Shapiro⁶, Carol A. Connell⁷, Arthur Kavanaugh⁸. ¹Albany Medical College, Center for Rheumatology, Albany, NY, United States of America; ²Johns Hopkins University, Baltimore, MD, United States of America; ³Corrona, LLC, Waltham, MA, United States of America; ⁴Pfizer Inc, New York, NY, United States of America; ⁵Colombia University, Department of Medicine, New York, NY, United States of America; ⁶Pfizer Inc, Peapack, NJ, United States of America; ⁷Pfizer Inc, Groton, CT, United States of America; ⁸University of California, San Diego School of Medicine, La Jolla, San Diego, CA, United States of America

Background: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Real-world data (RWD) complement clinical trial data in assessing

long-term safety. To our knowledge, this is the first long-term comparative RWD analysis of tofacitinib.

Objectives: To compare 5-year adverse event (AE) incidence rates (IRs) in patients (pts) starting tofacitinib vs biological (b)DMARDs using cohorts from the US Corrona RA registry.

Methods: This prospective, observational 5-year study embedded in the ongoing US Corrona RA registry routinely collected 9 categories of predefined AEs from participating physicians. Real-world safety event rates of major adverse cardiovascular events (MACE), serious infectious events (SIEs) and herpes zoster (HZ; serious and non-serious) were compared in pts with RA who started tofacitinib or a bDMARD regardless of dose/schedule between 6 Nov 2012 (US FDA approval) and 30 Jun 2017 (follow-up through 31 Dec 2017). Endpoints were selected *a priori* as having sufficient power to detect a 2-fold difference between cohorts at this datacut; there was insufficient power to assess malignancy. Baseline variables with a standardised difference $>|0.10|$ between tofacitinib and bDMARD initiators, and *a priori* selected covariates (gender, age, line of therapy, history of AE of interest) were used to construct propensity scores (PS) to derive a PS-trimmed (primary) population and a PS-matched population for sensitivity analysis (ratio: max. 4 bDMARD:1 tofacitinib; caliper=0.05). Pts were followed from initiation until an AE of interest, discontinuation and/or start of a new therapy +90 days, death or end of follow-up, whichever came first. Crude IRs (events/100 pt-years [PY]) were estimated; multivariable-adjusted Cox regression was used to estimate hazard ratios (HRs) comparing rates of first events between cohorts.

Results: In total, 1544 tofacitinib (2138.2 PY) and 7083 bDMARD (9904.9 PY) initiators were included. PS-trimming resulted in 1117 tofacitinib and 5542 bDMARD initiators. Rates of MACE and SIEs were similar in both cohorts (Fig 1A); adjusted HRs (95% confidence intervals [CIs]) were: MACE 0.60 (0.30, 1.18); SIEs 0.99 (0.72, 1.36; Fig 1B). HZ IR was higher for tofacitinib vs bDMARDs (Fig 1A); HRs for HZ were significantly increased with tofacitinib vs bDMARDs (adjusted HR 2.12 [1.22, 3.66]; Fig 1B); all HZ events were non-serious with tofacitinib. Similar results were observed in PS-matched populations.

FIG 1: A. Crude incidence rates* for MACE, SIEs and HZ; and B. Hazard ratios for MACE, SIEs and HZ

*Incidence rates are events per 100 PY. MACE is defined as any myocardial infarction, stroke/transient ischaemic attack or cardiovascular death.

bDMARD, biological disease-modifying antirheumatic drug; CI, confidence interval; HR, hazard ratio; HZ, herpes zoster; MACE, major adverse cardiovascular event; PS, propensity score; PY, patient-years; SIEs, serious infectious events

Conclusion: This is the first comparative analysis of RWD for tofacitinib and bDMARDs to use PS-trimmed and PS-matched analyses to adjust for channeling/prescribing patterns for newly approved therapies. Pts starting tofacitinib or bDMARDs for RA had similar rates of MACE and SIEs. Tofacitinib initiators had

higher HZ IRs vs bDMARD initiators. These results are consistent with long-term clinical trial findings.

Acknowledgement: Sponsors: Corrona, LLC. Corrona is supported by contracted subscriptions with multiple companies. This was a Corrona/Pfizer collaboration with Pfizer financial support. Medical writing support provided by Anthony G McCluskey of CMC Connect and funded by Pfizer Inc.

Disclosure of Interests: Joel Kremer Grant/research support from: AbbVie, Genentech, Lilly, Novartis, Pfizer, Consultant for: AbbVie, Amgen, BMS, Genentech, Lilly, Regeneron, Sanofi, Pfizer, Clifton Bingham Grant/research support from: BMS, Consultant for: AbbVie, BMS, Eli Lilly, Genentech/Roche, Janssen, Pfizer, Sanofi/Regeneron, Laura Cappelli Grant/research support from: Bristol-Myers Squibb, Consultant for: Regeneron/Sanofi Genzyme, Carol Etzel Shareholder of: Corrona, LLC, Consultant for: Merck, Employee of: Corrona, LLC, Jeffrey Greenberg Shareholder of: Corrona, LLC, Consultant for: Eli Lilly, Genentech, Janssen, Novartis, and Pfizer Inc, Employee of: Corrona, LLC, Jamie Geier Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Ann Madsen Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Connie Chen Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Alina Onofrei Employee of: Corrona, LLC, Christine Barr Shareholder of: Corrona, LLC, Employee of: Corrona, LLC, Dimitrios A Pappas Grant/research support from: AbbVie, Consultant for: AbbVie, Employee of: Corrona, Heather J. Litman: None declared, Kimberly J Dandreo Employee of: Corrona, LLC, Andrea Shapiro Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Carol A. Connell Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Arthur Kavanaugh Grant/research support from: UCB Pharma

DOI: 10.1136/annrheumdis-2019-eular.621

OP0029 SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS

Mark C. Genovese¹, Roy Fleischmann², Ricardo Blanco³, Stephen Hall⁴, Glen Thomson⁵, Filip van den Bosch⁶, Cristiano Zerbini⁷, Jose Jeffrey Enejoa⁸, Li Yihan⁹, Ryan Demasi⁹, In-Ho Song⁹. ¹Stanford University, Palo Alto, United States of America; ²Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, United States of America; ³Hospital Universitario Marqués de Valdecilla, Santander, Spain; ⁴Monash University, Cabrini Health and Emeritus Research, Malvern, Australia; ⁵CIADS Research, Winnipeg, Canada; ⁶Ghent University Hospital, Ghent, Belgium; ⁷Paulista Center for Clinical Research, São Paulo, Brazil; ⁸AbbVie, Inc., North Chicago, United States of America

Background: Initiating advanced therapy for rheumatoid arthritis (RA) patients (pts) with a bDMARD or a Janus kinase (JAK) inhibitor is recommended if remission or low disease activity (LDA) is not achieved with csDMARDs.^{1,2} While data show that pts are switched alternately between bDMARD and JAK treatments, there is lack of evidence for pts with inadequate response (IR) to a JAK inhibitor switching to a bDMARD. Recently, the JAK1-selective inhibitor-upadacitinib (UPA) demonstrated superior clinical and functional outcomes through 26 wks to the standard of care-adalimumab (ADA) with continued background methotrexate (MTX).³

Objectives: To describe outcomes associated with treatment switch from UPA to ADA and vice-versa among RA pts who do not achieve initial response.

Methods: This phase 3, double-blind, placebo (PBO)-controlled, head-to-head study of UPA 15 mg q.d. vs PBO or ADA 40 mg injection every other wk included MTX-IR patients; all pts continued stable background MTX through 26 wks. Pts without $\geq 20\%$ improvements from bl in tender (68) and swollen (66) joint counts by wks 14, 18, or 22 were considered non-responders (NR) and switched without washout to either ADA (UPA group) or UPA (ADA group) in a bl fashion. Post-hoc analysis assessed clinical outcomes - DAS28 (CRP), CDAI, SDAI, and ACR responses (from baseline), and HAQ-DI at 3 and 6 mos (± 2 wks) post-switch. Adverse events (infections) were summarized as n% (95% CI) through 6 mos post-switch (ps). Data were as observed.

n/N (%)	UPA 15 mg QD Non-responders Switched to ADA 40 mg eow (N=126)		ADA 40 mg eow Non-responders Switched to UPA 15 mg QD (N=77)	
	3 months post-switch	6 months post-switch	3 months post-switch	6 months post-switch
ACR20*	68/118 (58)	67/113 (59)	49/75 (65)	53/71 (75)
ACR50*	33/120 (28)	29/112 (26)	26/73 (36)	34/69 (49)
ACR70*	10/120 (8)	14/114 (12)	13/74 (18)	17/71 (24)
DAS28(CRP) <3.2	30/119 (25)	38/109 (35)	31/74 (42)	38/70 (54)
DAS28(CRP) <2.6	15/119 (13)	21/109 (19)	19/74 (26)	22/70 (31)
CDAI <10	33/120 (28)	42/114 (36)	24/72 (33)	39/70 (57)
SDAI <8	5/120 (4)	6/114 (5)	6/72 (8)	10/70 (14)
SDAI <11	32/119 (27)	41/109 (38)	26/71 (37)	33/69 (48)
SDAI <13	5/119 (4)	4/109 (4)	5/71 (7)	13/69 (17)
Mean change from baseline (95% CI)				
HAQ-DI	-0.49 (-0.66, -0.38)	-0.52 (-0.64, -0.41)	-0.63 (-0.76, -0.50)	-0.67 (-0.81, -0.53)
DAS28(CRP)	-1.79 (-2.03, -1.55)	-2.10 (-2.36, -1.84)	-2.36 (-2.66, -2.08)	-2.56 (-2.80, -2.32)
CDAI	-20.87 (-23.62, -18.11)	-24.51 (-26.48, -22.53)	-24.51 (-26.48, -22.53)	-24.51 (-26.48, -22.53)
SDAI	-21.70 (-24.46, -18.94)	-24.52 (-27.47, -21.56)	-23.49 (-27.03, -19.95)	-26.07 (-29.56, -22.59)

*Responses are based on percent improvement in American College of Rheumatology criteria from baseline at randomization; Mean change from baseline at randomization. UPA: upadacitinib; QD: once daily; ADA: adalimumab; eow: every other week; ACR: American College of Rheumatology; DAS28(CRP): 28-joint disease activity score based on C-reactive protein; CDAI: clinical disease activity index; SDAI: simplified disease activity index; CI: confidence interval; TCSD: tender joint count based on 68 joints; TCSD: swollen joint count based on 66 joints; HAQ-DI: health assessment questionnaire disability index.